# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ProSomnus (NASDAQ:OSA) reported quarterly sales of $7.84 million which beat the analyst consensus estimate of $7.37 million by ...
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced re...
Alliance Global Partners analyst Scott Henry initiates coverage on ProSomnus (NASDAQ:OSA) with a Buy rating and announces Pr...
ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the...
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with t...